vs
Side-by-side financial comparison of Cushman & Wakefield Ltd. (CWK) and Organon & Co. (OGN). Click either name above to swap in a different company.
Cushman & Wakefield Ltd. is the larger business by last-quarter revenue ($2.9B vs $1.5B, roughly 1.9× Organon & Co.). Cushman & Wakefield Ltd. runs the higher net margin — -0.8% vs -13.6%, a 12.8% gap on every dollar of revenue. On growth, Cushman & Wakefield Ltd. posted the faster year-over-year revenue change (10.8% vs -5.3%). Cushman & Wakefield Ltd. produced more free cash flow last quarter ($234.3M vs $96.0M). Over the past eight quarters, Cushman & Wakefield Ltd.'s revenue compounded faster (15.5% CAGR vs -3.6%).
Cushman & Wakefield Inc. is an American global commercial real estate and property management services firm. The company's corporate headquarters is located in Chicago, Illinois. It is named after co-founders J. Clydesdale Cushman and Bernard Wakefield.
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.
CWK vs OGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9B | $1.5B |
| Net Profit | $-22.4M | $-205.0M |
| Gross Margin | — | 49.2% |
| Operating Margin | 6.1% | -9.8% |
| Net Margin | -0.8% | -13.6% |
| Revenue YoY | 10.8% | -5.3% |
| Net Profit YoY | -119.8% | -288.1% |
| EPS (diluted) | $-0.10 | $-0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9B | $1.5B | ||
| Q3 25 | $2.6B | $1.6B | ||
| Q2 25 | $2.5B | $1.6B | ||
| Q1 25 | $2.3B | $1.5B | ||
| Q4 24 | $2.6B | $1.6B | ||
| Q3 24 | $2.3B | $1.6B | ||
| Q2 24 | $2.3B | $1.6B | ||
| Q1 24 | $2.2B | $1.6B |
| Q4 25 | $-22.4M | $-205.0M | ||
| Q3 25 | $51.4M | $160.0M | ||
| Q2 25 | $57.3M | $145.0M | ||
| Q1 25 | $1.9M | $87.0M | ||
| Q4 24 | $112.9M | $109.0M | ||
| Q3 24 | $33.7M | $359.0M | ||
| Q2 24 | $13.5M | $195.0M | ||
| Q1 24 | $-28.8M | $201.0M |
| Q4 25 | — | 49.2% | ||
| Q3 25 | — | 53.5% | ||
| Q2 25 | — | 54.8% | ||
| Q1 25 | — | 55.6% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 58.3% | ||
| Q2 24 | — | 58.4% | ||
| Q1 24 | — | 59.0% |
| Q4 25 | 6.1% | -9.8% | ||
| Q3 25 | 4.1% | 15.2% | ||
| Q2 25 | 4.9% | 14.4% | ||
| Q1 25 | 2.0% | 6.7% | ||
| Q4 24 | 6.6% | 8.1% | ||
| Q3 24 | 3.2% | 13.1% | ||
| Q2 24 | 3.1% | 14.6% | ||
| Q1 24 | 0.9% | 14.5% |
| Q4 25 | -0.8% | -13.6% | ||
| Q3 25 | 2.0% | 10.0% | ||
| Q2 25 | 2.3% | 9.1% | ||
| Q1 25 | 0.1% | 5.8% | ||
| Q4 24 | 4.3% | 6.8% | ||
| Q3 24 | 1.4% | 22.7% | ||
| Q2 24 | 0.6% | 12.1% | ||
| Q1 24 | -1.3% | 12.4% |
| Q4 25 | $-0.10 | $-0.78 | ||
| Q3 25 | $0.22 | $0.61 | ||
| Q2 25 | $0.25 | $0.56 | ||
| Q1 25 | $0.01 | $0.33 | ||
| Q4 24 | $0.49 | $0.42 | ||
| Q3 24 | $0.14 | $1.38 | ||
| Q2 24 | $0.06 | $0.75 | ||
| Q1 24 | $-0.13 | $0.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $784.2M | $574.0M |
| Total DebtLower is stronger | $2.7B | $8.6B |
| Stockholders' EquityBook value | $2.0B | $752.0M |
| Total Assets | $7.7B | $12.9B |
| Debt / EquityLower = less leverage | 1.40× | 11.49× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $784.2M | $574.0M | ||
| Q3 25 | $634.4M | $672.0M | ||
| Q2 25 | $618.2M | $599.0M | ||
| Q1 25 | $623.2M | $547.0M | ||
| Q4 24 | $793.3M | $675.0M | ||
| Q3 24 | $775.4M | $763.0M | ||
| Q2 24 | $567.3M | $704.0M | ||
| Q1 24 | $553.5M | $575.0M |
| Q4 25 | $2.7B | $8.6B | ||
| Q3 25 | $2.8B | $8.8B | ||
| Q2 25 | $3.0B | $8.9B | ||
| Q1 25 | $3.0B | $9.0B | ||
| Q4 24 | $3.0B | $8.9B | ||
| Q3 24 | $3.1B | $8.7B | ||
| Q2 24 | $3.1B | $8.7B | ||
| Q1 24 | $3.2B | $8.7B |
| Q4 25 | $2.0B | $752.0M | ||
| Q3 25 | $2.0B | $906.0M | ||
| Q2 25 | $1.9B | $733.0M | ||
| Q1 25 | $1.8B | $542.0M | ||
| Q4 24 | $1.8B | $472.0M | ||
| Q3 24 | $1.7B | $493.0M | ||
| Q2 24 | $1.6B | $144.0M | ||
| Q1 24 | $1.6B | $48.0M |
| Q4 25 | $7.7B | $12.9B | ||
| Q3 25 | $7.7B | $13.6B | ||
| Q2 25 | $7.6B | $13.5B | ||
| Q1 25 | $7.4B | $13.2B | ||
| Q4 24 | $7.5B | $13.1B | ||
| Q3 24 | $7.5B | $12.8B | ||
| Q2 24 | $7.3B | $12.2B | ||
| Q1 24 | $7.5B | $11.9B |
| Q4 25 | 1.40× | 11.49× | ||
| Q3 25 | 1.45× | 9.74× | ||
| Q2 25 | 1.57× | 12.14× | ||
| Q1 25 | 1.70× | 16.52× | ||
| Q4 24 | 1.73× | 18.81× | ||
| Q3 24 | 1.81× | 17.75× | ||
| Q2 24 | 1.91× | 60.11× | ||
| Q1 24 | 1.96× | 181.54× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $257.3M | $141.0M |
| Free Cash FlowOCF − Capex | $234.3M | $96.0M |
| FCF MarginFCF / Revenue | 8.0% | 6.4% |
| Capex IntensityCapex / Revenue | 0.8% | 3.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $293.0M | $538.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $257.3M | $141.0M | ||
| Q3 25 | $235.5M | $264.0M | ||
| Q2 25 | $9.6M | $220.0M | ||
| Q1 25 | $-162.0M | $75.0M | ||
| Q4 24 | $115.2M | $390.0M | ||
| Q3 24 | $196.1M | $141.0M | ||
| Q2 24 | $21.8M | $332.0M | ||
| Q1 24 | $-125.1M | $76.0M |
| Q4 25 | $234.3M | $96.0M | ||
| Q3 25 | $225.0M | $218.0M | ||
| Q2 25 | $300.0K | $181.0M | ||
| Q1 25 | $-166.6M | $43.0M | ||
| Q4 24 | $105.9M | $335.0M | ||
| Q3 24 | $186.7M | $99.0M | ||
| Q2 24 | $10.0M | $300.0M | ||
| Q1 24 | $-135.6M | $30.0M |
| Q4 25 | 8.0% | 6.4% | ||
| Q3 25 | 8.6% | 13.6% | ||
| Q2 25 | 0.0% | 11.4% | ||
| Q1 25 | -7.3% | 2.8% | ||
| Q4 24 | 4.0% | 21.0% | ||
| Q3 24 | 8.0% | 6.3% | ||
| Q2 24 | 0.4% | 18.7% | ||
| Q1 24 | -6.2% | 1.8% |
| Q4 25 | 0.8% | 3.0% | ||
| Q3 25 | 0.4% | 2.9% | ||
| Q2 25 | 0.4% | 2.4% | ||
| Q1 25 | 0.2% | 2.1% | ||
| Q4 24 | 0.4% | 3.5% | ||
| Q3 24 | 0.4% | 2.7% | ||
| Q2 24 | 0.5% | 2.0% | ||
| Q1 24 | 0.5% | 2.8% |
| Q4 25 | — | — | ||
| Q3 25 | 4.58× | 1.65× | ||
| Q2 25 | 0.17× | 1.52× | ||
| Q1 25 | -85.26× | 0.86× | ||
| Q4 24 | 1.02× | 3.58× | ||
| Q3 24 | 5.82× | 0.39× | ||
| Q2 24 | 1.61× | 1.70× | ||
| Q1 24 | — | 0.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CWK
| Equity Method Investment Nonconsolidated Investee Or Group Of Investees | $1.8B | 61% |
| Other | $1.1B | 39% |
OGN
Segment breakdown not available.
